Boston Scien Cp SEC Filings

Boston Scientific (BSX) has a holder planning to sell 17,313 shares of its common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $1,758,187.73 as disclosed. The shares relate to a stock option exercise dated 12/01/2025, paid in cash to the issuer on the same date, meaning the company received cash for the option exercise while the holder expects to receive cash proceeds from the market sale. Boston Scientific had 1,482,442,039 shares of common stock outstanding as context for the planned transaction.

Boston Scientific Corporation reported that its Board approved a new 2026 Annual Bonus Plan and two 2026 performance share programs for executive officers and other eligible employees. The cash bonus plan, covering the 2026 performance year, ties payouts to company-wide goals for global sales, adjusted earnings per share, operating income as a percent of sales, and corporate sustainability goals, with an aggregate bonus pool based on target bonuses and a distribution percentage between 0% and 150%. Individual awards can range from 0% to 225% of a participant’s target bonus through performance modifiers.

The Board also adopted the 2026 Relative Total Shareholder Return Performance Share Program, which measures total shareholder return against the S&P 500 Healthcare Index over a three-year period from January 1, 2026 to December 31, 2028, and the 2026 Organic Net Sales Growth Performance Share Program, which measures organic net sales growth versus the company’s financial plan over the same period. Under both programs, awards in the form of restricted stock units can range from 0% to 200% of target and vest only if performance and payment eligibility criteria are met, with clawback and recoupment policies applying to covered executive officers.

Boston Scientific (BSX) executive EVP & Group President, Cardiology, reported two bona fide gifts of common stock. The filings show a Code G transaction for 690 shares on 11/12/2025 at $0.0000, followed by a Code G transaction for 9,610 shares on 11/14/2025 at $0.0000.

After these transactions, the reporting person held 168,042 shares directly. An additional 5,234 shares are listed as held indirectly by child, with a stated disclaimer of beneficial ownership.

Boston Scientific (BSX) director reported an open‑market sale of 12,891 common shares on November 6, 2025 at a weighted average price of $98.2839, executed under a pre‑established Rule 10b5-1 trading plan adopted on July 25, 2025.

The filing notes sales occurred across a price range of $97.89 to $98.65. Following the transaction, the reporting person beneficially owns 24,134 shares directly.

Boston Scientific (BSX) filed a Form 144/A notice covering a proposed sale of up to 2,901 common shares with an aggregate market value of $284,171.33. The filing lists Wells Fargo Clearing Services as broker and an approximate sale date of 11/06/2025 on the NYSE.

The shares were acquired via a stock grant on 05/01/2025 in the amount of 2,901. This notice signals an intended sale by or for the account of the person named in the filing under Rule 144.

Boston Scientific (BSX) reported an insider transaction by its EVP & Group President, Cardiology. On 11/03/2025, the officer exercised 50,000 stock options at $26.15 and sold a total of 50,000 common shares in three trades at $100.7481 (3,600 shares), $99.7607 (16,928), and $99.1414 (29,472), pursuant to a pre-established Rule 10b5-1 plan adopted on February 27, 2025.

Following these transactions, the officer directly owns 178,342 shares and indirectly holds 5,234 shares through a child.

Boston Scientific (BSX) insider Joseph M. Fitzgerald filed a Form 144 indicating an intended sale of 50,000 shares of common stock, with an aggregate market value $4,973,335. The sales are planned for approximately 11/03/2025 on the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services.

The shares were acquired via stock option exercise on 11/03/2025 for cash. As context, 1,482,442,039 shares were outstanding. Over the past three months, Fitzgerald sold 50,000 shares on 10/01/2025 for $4,923,325 and 50,000 shares on 09/02/2025 for $5,271,415.

Boston Scientific reported stronger results for Q3 2025. Net sales rose to $5,065 million from $4,209 million a year ago, lifting gross profit to $3,542 million. Operating income increased to $1,048 million from $733 million, and net income attributable to common stockholders reached $755 million versus $469 million. Diluted EPS was $0.51 compared with $0.32. For the first nine months, net sales were $14,788 million (vs. $12,186 million) and net income was $2,226 million (vs. $1,288 million).

Cash from operations for the nine months rose to $3,170 million from $1,979 million, supporting a series of acquisitions: Bolt Medical ($475 million upfront, up to $200 million future), SoniVie ($362 million upfront, up to $200 million future), Intera Oncology ($172 million), Cortex ($239 million upfront, up to $50 million future), Anrei Medical ($182 million), and another business ($73 million). The company also announced a definitive agreement to acquire Nalu Medical with an upfront cash payment of approximately $533 million upon closing, expected in the first half of 2026, subject to customary conditions.

Boston Scientific (BSX) Chairman, President & CEO and Director Michael F. Mahoney filed a Form 4 reporting gifts of common stock involving trusts. On 10/29/2025, Code G entries recorded 88,197 shares (A) and 73,996 shares (A) at $0.0000, with indirect ownership noted as “By Trust.”

On 10/30/2025, a Code G entry recorded 149,992 shares (D) at $0.0000, with indirect ownership noted as “By Trust.” The footnotes state the transactions involved gifts by The Michael F. Mahoney 2 Year Qualified Annuity Trust – 2023 and – 2024, and a gift by the reporting person to The Michael F. Mahoney Term Irrevocable Trust – 2025, each administered by an independent trustee.